Cortex Begins Human Trials of Alzheimer’s Drug
- Share via
IRVINE — Cortex Pharmaceuticals Inc. has started human clinical trials with a drug it is developing for treatment of memory loss resulting from Alzheimer’s disease.
The firm said the study of its Ampakine product is aimed at gaining knowledge of the safety of the compound on humans. The study, being conducted in Berlin, involves 48 people and will last about six weeks. Earlier this year, the company reported that tests of Ampakine on rats showed that animals treated with the drug performed significantly better than untreated animals.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
